Utility of NSE, ProGRP, VEGFA and CSI in diagnostics of small cell lung cancer patients

Ewa Wójcik; Zofia Stasik; Beata Sas-Korczyńska; Krystyna Sobolewska; Stanisław Korzeniowski; Piotr Skotnicki; Jan Kanty Kulpa

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2009
vol. 13

Send email

Copy url:

abstract:

Original paper

Utility of NSE, ProGRP, VEGFA and CSI in diagnostics of small cell lung cancer patients

Ewa Wójcik

,

Zofia Stasik

,

Beata Sas-Korczyńska

,

Krystyna Sobolewska

,

Stanisław Korzeniowski

,

Piotr Skotnicki

,

Jan Kanty Kulpa

Współczesna Onkologia (2009) vol. 13; 2 (95-101)

Online publish date: 2009/05/04

View full text Get citation

Aim of the study: Assessment of clinical utility of VEGF results, selected tumour markers (NSE and ProGRP), and the cancer serum index (CSI) was performed with respect to their prognostic value in small cell lung cancer (SCLC) patients.
Material and methods: The determination of NSE, ProGRP, VEGFA, alpha-1 acid glycoprotein and prealbumin concentrations and platelet counts was carried out before treatment in 72 patients with SCLC (40 with limited and 32 with extensive disease). The same set of parameters was determined in the reference group consisting of healthy persons. The Cancer Serum Index was calculated for each studied person as the ratio of alpha-1 acid glycoprotein to prealbumin.
Results: Areas under ROC curves were respectively: for ProGRP: 0.943 ±0.03; NSE: 0.869 ±0.04; CSI: 0.838 ±0.04; VEGFA: 0.713 ±0.05. The relatively highest diagnostic sensitivity was found for ProGRP. The frequency of elevated NSE, VEGF and CSI results were related to the extent of disease, whereas lack of such dependencies was observed for ProGRP. Relationships were found between time of survival and advancement of disease as well as initial values of studied parameters. Extent of disease and higher than discriminant value of ProGRP and VEGFA concentrations count among the independent and unfavourable prognostic factors in SCLC patients. Patients with extensive disease as well as with pre-treatment ProGRP concentrations above 670 ng/l and exceeding VEGFA level 420 ng/ml showed 2.5 times higher risk of death.

keywords:

Utility of NSE, ProGRP, VEGFA and CSI in diagnostics of small cell lung cancer patients

Ewa Wójcik , Zofia Stasik , Beata Sas-Korczyńska , Krystyna Sobolewska , Stanisław Korzeniowski , Piotr Skotnicki , Jan Kanty Kulpa

small cell lung cancer, vascular endothelial growth factor, prognosis

Ewa Wójcik

,

Zofia Stasik

,

Beata Sas-Korczyńska

,

Krystyna Sobolewska

,

Stanisław Korzeniowski

,

Piotr Skotnicki

,

Jan Kanty Kulpa